AR059423A1 - Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables - Google Patents

Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables

Info

Publication number
AR059423A1
AR059423A1 ARP070100554A ARP070100554A AR059423A1 AR 059423 A1 AR059423 A1 AR 059423A1 AR P070100554 A ARP070100554 A AR P070100554A AR P070100554 A ARP070100554 A AR P070100554A AR 059423 A1 AR059423 A1 AR 059423A1
Authority
AR
Argentina
Prior art keywords
agonists
therapeutic agents
oral administration
waterproof
unions
Prior art date
Application number
ARP070100554A
Other languages
English (en)
Inventor
Natalie D Eddington
Alessio Fasano
Tae Keun Song
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of AR059423A1 publication Critical patent/AR059423A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente provee composiciones y métodos para la administracion de composiciones a mamíferos, las composiciones comprenden agentes terapéuticos y una cantidad mejoradota de la absorcion intestinal de uno o más agonistas de uniones impermeables. Los agonistas de uniones impermeables incluyen agonistas de receptores de zonulina y/o ZOT. Los métodos incluyen la administracion oral de composiciones de la invencion.
ARP070100554A 2006-02-09 2007-02-09 Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables AR059423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77145306P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
AR059423A1 true AR059423A1 (es) 2008-04-09

Family

ID=38372019

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100554A AR059423A1 (es) 2006-02-09 2007-02-09 Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables

Country Status (6)

Country Link
US (1) US20070196272A1 (es)
EP (1) EP1993356A2 (es)
AR (1) AR059423A1 (es)
CL (1) CL2007000345A1 (es)
TW (1) TW200738269A (es)
WO (1) WO2007095091A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20110046079A1 (en) * 2008-01-16 2011-02-24 Mullin James M Use of Proton Pump Inhibitors as Drug Delivery Adjuvants
CA2963659C (en) 2008-09-17 2020-06-23 Chiasma Inc. Use of oral octreotride compositions
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
CN102781476A (zh) * 2009-11-18 2012-11-14 墨累古尔本合作有限公司 改进经口递送的方法
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
KR101470793B1 (ko) 2014-06-30 2014-12-08 순천향대학교 산학협력단 흡수촉진제로서의 펩타이드와 이를 포함하는 조성물
MA41159A (fr) 2014-12-10 2021-05-12 Chiasma Inc Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
EP3253401A4 (en) 2015-02-03 2018-11-21 Chiasma Inc. Method of treating diseases
WO2020091535A1 (ko) * 2018-11-02 2020-05-07 순천향대학교 산학협력단 점막 투과 촉진용 펩타이드 및 이를 포함하는 조성물
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
KR20220150361A (ko) * 2021-02-26 2022-11-10 씨큐어 타이완 씨오., 엘티디. 티오퓨린계 화합물, 조성물, 제조 방법 및 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60314495T2 (de) * 2002-02-07 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern
EP1648917A4 (en) * 2003-07-15 2008-11-12 Univ Maryland AGONISTPOLYPEPTIDE OF THE RECEPTOR FOR ZOT AND ZONULIN

Also Published As

Publication number Publication date
WO2007095091A2 (en) 2007-08-23
WO2007095091A3 (en) 2008-09-12
EP1993356A2 (en) 2008-11-26
TW200738269A (en) 2007-10-16
US20070196272A1 (en) 2007-08-23
CL2007000345A1 (es) 2008-01-11

Similar Documents

Publication Publication Date Title
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
ATE502921T1 (de) Substituierte indole
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CL2008002539A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
CO6660445A2 (es) Compuestos heterocíclicos agonistas del receptor ip
DK2077729T3 (da) Orale probiotiske doseringsformer
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ECSP11011327A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
ECSP088222A (es) Agonistas de receptores adrenérgicos alfa2c funcionalmente selectivos
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
GT200600117A (es) Nuevos compuestos farmaceuticos
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
UY33348A (es) Compuestos de furopiridina y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure